KNE — Kane Biotech Balance Sheet
0.000.00%
- CA$14.70m
- CA$16.44m
- CA$0.15m
Annual balance sheet for Kane Biotech, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.834 | 1.01 | 1.15 | 1.1 | 0.749 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.362 | 1.12 | 1.07 | 1.06 | 0.103 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 1.84 | 2.74 | 2.88 | 3.1 | 3.72 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.08 | 0.163 | 1.44 | 1.25 | 1.07 |
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 2.76 | 5.04 | 6.13 | 5.62 | 5.68 |
Accounts Payable | |||||
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.34 | 2.92 | 4.72 | 6.34 | 10.9 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.92 | 6.53 | 10 | 12.1 | 16.2 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 0.837 | -1.49 | -3.89 | -6.52 | -10.6 |
Total Liabilities & Shareholders' Equity | 2.76 | 5.04 | 6.13 | 5.62 | 5.68 |
Total Common Shares Outstanding |